Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Ophthalmic Drug Delivery Systems01:23

Ophthalmic Drug Delivery Systems

222
Ophthalmic drug delivery faces major limitations due to poor absorption across the corneal membrane. This process is primarily driven by diffusion and is influenced by two main factors: the physicochemical properties of the drug and tear drainage. Most ophthalmic drugs, such as pilocarpine, epinephrine, atropine, and local anesthetics, are weak bases. They are typically formulated at an acidic pH to enhance chemical stability. However, this leads to high ionization, reducing their ability to...
222
Glaucoma: Overview01:25

Glaucoma: Overview

1.7K
Glaucoma is an eye condition characterized by increased intraocular pressure that damages the retina and optic nerve, leading to irreversible blindness if left untreated. The human eye has various components, including the cornea, iris, pupil, lens, and optic nerve. Aqueous humor is secreted by the epithelium of the ciliary body in the posterior chamber and flows through the trabecular meshwork and canal of Schlemm, maintaining normal intraocular pressure. The trabecular meshwork and the canal...
1.7K
Open Angle Glaucoma: Treatment01:27

Open Angle Glaucoma: Treatment

1.1K
In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
1.1K
Accessory Structures of the Eye01:17

Accessory Structures of the Eye

4.4K
Optical perception, or vision, is an extraordinary sense dependent on converting light signals received via the ocular organs. These organs, known as eyes, are securely positioned within the bony cavities of the skull, called orbits. The orbits serve a dual purpose: a protective shield for the ocular globes and a stable attachment point for the soft ocular tissues. The eye's external protective mechanisms include the eyelids, which are edged with lashes that act as a barrier against foreign...
4.4K
Angle Closure Glaucoma: Treatment01:28

Angle Closure Glaucoma: Treatment

1.6K
Angle-closure glaucoma, or closed-angle glaucoma, is an eye condition where the iris bulges out and blocks the iridocorneal angle, resulting in a buildup of aqueous humor and increased intraocular pressure. Immediate medical attention is necessary due to the sudden onset of symptoms. The treatment for angle-closure glaucoma includes short-term and long-term approaches. Short-term treatment involves using eye drops like pilocarpine to lower intraocular pressure by increasing aqueous humor...
1.6K
Photoreceptors and Visual Pathways01:22

Photoreceptors and Visual Pathways

11.1K
At the molecular level, visual signals trigger transformations in photopigment molecules, resulting in changes in the photoreceptor cell's membrane potential. The photon's energy level is denoted by its wavelength, with each specific wavelength of visible light associated with a distinct color. The spectral range of visible light, classified as electromagnetic radiation, spans from 380 to 720 nm. Electromagnetic radiation wavelengths exceeding 720 nm fall under the infrared category,...
11.1K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Pipeline: Eugene Garfield, Ph.D. and Bibliometrics.

The ocular surface·2026
Same author

Eyes on New Product Development-Number 134.

Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics·2026
Same author

Use of Clinical Pharmacology in Slowing the Myopia Epidemic.

Clinical pharmacology and therapeutics·2026
Same author

Eyes on New Product Development-Number 133.

Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics·2026
Same author

Remote Tonometry Identifies Significant Variability in the Timing of Intraocular Pressure Response to Topical Medication Change.

Ophthalmology. Glaucoma·2026
Same author

History of the American Journal of Ophthalmology in the Late 20th Century.

American journal of ophthalmology·2026
Same journal

FDA Gene Therapy Approvals (1998-2025): Current Status, Regulatory Evolution, and Future Directions.

Journal of clinical pharmacology·2026
Same journal

Human Disposition, Metabolism, and Excretion of Sevasemten (EDG-5506), a Selective Modulator of Fast Myosin in Healthy Volunteers.

Journal of clinical pharmacology·2026
Same journal

New Insights into Genetic Polymorphisms Influencing the Therapeutic Efficacy and Toxicity of Rivaroxaban.

Journal of clinical pharmacology·2026
Same journal

Physiologically Based Pharmacokinetic Modeling to Predict the Pharmacokinetics of Sacubitril/Valsartan in the Elderly with Renal or Hepatic Impairment Population.

Journal of clinical pharmacology·2026
Same journal

The Journal of Clinical Pharmacology: 65 Years of History.

Journal of clinical pharmacology·2026
Same journal

Decoupling CAR-T Expansion, Conversion, and Decay Timing: Physiologically Aligned Semi-Mechanistic Modeling With Smooth Gating and a Cauchy Likelihood Residual Model.

Journal of clinical pharmacology·2026
See all related articles

Related Experiment Video

Updated: Apr 4, 2026

Use of Rabbit Eyes in Pharmacokinetic Studies of Intraocular Drugs
10:02

Use of Rabbit Eyes in Pharmacokinetic Studies of Intraocular Drugs

Published on: July 23, 2016

33.7K

Ocular pharmacology.

Gary D Novack1,2, Alan L Robin3,4,5

  • 1PharmaLogic Development, Inc., San Rafael, CA, USA.

Journal of Clinical Pharmacology
|September 12, 2015
PubMed
Summary
This summary is machine-generated.

Ophthalmic drug delivery faces challenges due to ocular barriers and patient instillation accuracy. Systemic absorption of eye drops can lead to serious side effects, necessitating careful pharmaceutical formulation.

Keywords:
glaucomamacular degenerationophthalmologypharmacology

More Related Videos

Full-Circle Cauterization of Limbal Vascular Plexus for Surgically Induced Glaucoma in Rodents
10:10

Full-Circle Cauterization of Limbal Vascular Plexus for Surgically Induced Glaucoma in Rodents

Published on: February 15, 2022

2.0K
Author Spotlight: A Novel Protocol for Intracameral Injections to Enhance Precision in Rodent Ophthalmology
06:19

Author Spotlight: A Novel Protocol for Intracameral Injections to Enhance Precision in Rodent Ophthalmology

Published on: May 31, 2024

1.9K

Related Experiment Videos

Last Updated: Apr 4, 2026

Use of Rabbit Eyes in Pharmacokinetic Studies of Intraocular Drugs
10:02

Use of Rabbit Eyes in Pharmacokinetic Studies of Intraocular Drugs

Published on: July 23, 2016

33.7K
Full-Circle Cauterization of Limbal Vascular Plexus for Surgically Induced Glaucoma in Rodents
10:10

Full-Circle Cauterization of Limbal Vascular Plexus for Surgically Induced Glaucoma in Rodents

Published on: February 15, 2022

2.0K
Author Spotlight: A Novel Protocol for Intracameral Injections to Enhance Precision in Rodent Ophthalmology
06:19

Author Spotlight: A Novel Protocol for Intracameral Injections to Enhance Precision in Rodent Ophthalmology

Published on: May 31, 2024

1.9K

Area of Science:

  • Ophthalmology
  • Pharmaceutics
  • Pharmacokinetics

Background:

  • Ophthalmic diseases encompass a range of conditions, some mirroring systemic diseases, others unique to the eye.
  • Topical eye drops are common for anterior segment diseases, requiring patient adherence and accurate self-administration.
  • Drug delivery to the posterior segment presents greater challenges due to additional anatomical and physiological barriers.

Purpose of the Study:

  • To review the complexities of ophthalmic drug delivery.
  • To highlight challenges in achieving therapeutic drug concentrations at target ocular sites.
  • To discuss the importance of pharmaceutics and potential systemic absorption of ocular medications.

Main Methods:

  • Review of ophthalmic disease treatment modalities.
  • Analysis of anatomical and physiological barriers to ocular drug penetration.
  • Discussion of pharmacokinetic considerations and formulation requirements for ophthalmic drugs.

Main Results:

  • Topical ocular delivery is hindered by barriers, making it more challenging than other routes.
  • Posterior segment treatment is particularly difficult, with intravitreal injections becoming a standard for some conditions.
  • The eye's metabolic enzymes (limited CYP450) and drug transporters influence pharmacokinetics.
  • Ocular drug formulation requires attention to solubility, pH, osmolarity, sterility, and stability.
  • Systemic absorption of ocular medications can cause significant adverse events.

Conclusions:

  • Effective ophthalmic drug delivery requires overcoming significant anatomical and physiological hurdles.
  • Optimized pharmaceutics are crucial for both local efficacy and minimizing systemic toxicity.
  • Understanding ocular pharmacokinetics is vital for developing safer and more effective ophthalmic treatments.